Tesamorelin

Tesamorelin, sold as Egrifta, is a synthetic version of growth hormone-releasing hormone, approved by the FDA to shrink the excess deep abdominal fat that comes with HIV-associated lipodystrophy in adults. No other GHRH analog holds a full approval backed by phase 3 evidence, which alone separates it from most of what gets sold in this category. Structurally it is the complete 44-amino-acid human GHRH sequence with a trans-2-hexenoic acid group attached at one end, which resists enzymatic breakdown and stretches its plasma half-life to roughly 26 to 38 minutes — considerably longer than the natural hormone manages.

The condition it treats involves visceral fat accumulating abnormally, frequently alongside fat disappearing from the limbs, driven partly by antiretroviral therapy and partly by a relative growth hormone deficiency that comes with HIV. Tesamorelin restores the body's own pulsatile GH release and the IGF-1 rise that follows, and that combination breaks down fat preferentially where it has collected around the organs. The phase 3 trials showed significant, durable reductions on CT against placebo, and the approval followed in 2010.

Off-label, it is used to chase visceral fat in people without HIV, to address growth hormone deficiency, to improve liver fat, and for metabolic or cognitive benefits attributed to normalizing the GH and IGF-1 axis. Compounded versions circulate through telehealth providers in the US, but they have no lawful route to exist: tesamorelin's application was deemed a biologics license on 23 March 2020, and the compounding pathways written into the Food, Drug, and Cosmetic Act cover drugs rather than licensed biologics. Whatever is being sold as compounded tesamorelin is not coming from that pathway, and carries none of the standardization the branded product does. Grade A for the approved indication, on multiple phase 3 randomized trials; grade B for the off-label metabolic uses, where the mechanism is sound but the data are smaller or come from secondary endpoints.

It binds GHRH receptors on the somatotroph cells of the anterior pituitary, switching on adenylyl cyclase and cAMP signaling, which drives GH out in pulses. The distinction from injecting growth hormone itself matters: this does not bypass the hypothalamic-pituitary axis, it amplifies pulses the body is already generating, so feedback through somatostatin and circulating IGF-1 stays intact. GH therefore rises within physiological range rather than well above it, which is the most likely explanation for how favorably it behaved in the trials [1].

Higher GH prompts the liver to make more IGF-1. Both hormones switch on hormone-sensitive lipase and suppress lipoprotein lipase inside fat cells, which tips the balance toward breaking fat down. Visceral fat responds to that more readily than fat under the skin, which is why the reduction shows up where it does. There is also an effect on liver fat that runs independently of any change in visceral volume, possibly through GH receptors in the liver itself [6], and evidence that the quality of fat tissue improves — lipid content within muscle and liver — beyond what a volume measurement would capture [4].

Two independent phase 3 randomized trials and a pooled analysis carry the weight here. The first enrolled 412 patients with HIV and abdominal fat accumulation into a 26-week double-blind placebo-controlled trial [1]. Daily 2 mg subcutaneous dosing cut visceral fat on CT by a mean of about 17.8%, against 3.2% on placebo. IGF-1 rose roughly 78%. Both patients and their physicians rated abdominal appearance as meaningfully improved. HbA1c did not differ significantly between the arms at 26 weeks.

A follow-up trial with an open-label extension to 52 weeks [2] found visceral fat continuing to fall through the first 26 weeks — and, importantly, returning in patients moved from drug to placebo during the extension. Whatever this does, it does only while being taken. The pooled analysis across both trials confirmed the efficacy findings and assembled the strongest safety dataset available [3]. Pooling every available randomized trial, a 2026 analysis confirmed both the visceral and the hepatic fat findings, alongside a favorable metabolic picture and no meaningful rise in new diabetes [5].

Outside the HIV indication, it has improved liver fat in both HIV-positive and HIV-negative groups, reducing intrahepatic lipid and FGF-21 in a small trial of GH augmentation [6]. A 2021 study showed visceral fat QUALITY improving — measured by CT density, a marker of inflammation and metabolic dysfunction in the tissue — independently of how much fat was lost [4], which suggests the benefit is not only about volume. Use in people without HIV who carry excess visceral fat or relative GH deficiency is mechanistically reasonable and has not been tested in an adequately powered randomized trial.

A separate thread looked at GHRH agonists and cognition. A 2012 trial split 152 older adults, some of them mildly cognitively impaired, between GHRH therapy and placebo across 20 weeks, and found improvement in executive function and verbal memory — consistent with what IGF-1 does for hippocampal plasticity [7]. That study used a different GHRH preparation, so it speaks to the mechanism rather than to this drug. No dedicated trial has established cognitive efficacy for tesamorelin itself.

The approved dose is 2 mg injected under the skin once a day, into the abdomen, rotating sites to limit local reactions. Reconstitute per the manufacturer's instructions and use it promptly or refrigerate briefly. Judge the response objectively: a CT or DXA reading of deep abdominal fat at 26 weeks — and if nothing meaningful has happened by then, stopping is the appropriate conclusion rather than persisting.

Off-label prescribers sometimes drop to 1 mg daily or dose on alternate days, to hold down cost and limit how far IGF-1 climbs. No published dose-finding study exists in non-HIV populations to justify any of those protocols. Monitor IGF-1 during treatment and keep it inside the age-adjusted normal range. Cycling — three to six months on, one to two off — is common off-label practice supported by anecdote rather than evidence. It is not for use in pregnancy or during active malignancy.

It was generally well tolerated across the phase 3 trials [1][3]. Injection-site reactions were the commonest complaint — redness, itching, pain — affecting up to a quarter of participants. Swelling in the limbs and joint pain turned up at low rates. Fasting glucose and insulin rose modestly and temporarily in some patients, which is what growth hormone does to insulin sensitivity; even so, HbA1c at 26 weeks looked no different from placebo, and the pooled 2026 analysis turned up no meaningful excess of new diabetes [5]. IGF-1 climbing around 78% is expected rather than alarming, and it does warrant monitoring in anyone at risk from IGF-1-sensitive conditions.

It is contraindicated with active malignancy, with a pituitary tumor or previous pituitary surgery, in pregnancy, and in anyone hypersensitive to GHRH or any component. Where injected growth hormone at supraphysiological doses is associated with acromegaly, amplifying the body's own pulses leaves the feedback loop intact, which should in theory limit overshoot. What is not known is long-term safety past 52 weeks in HIV populations, or past any duration at all outside them. And compounded material from outside licensed pharmacies adds the usual risks of contamination and mislabeled potency on top of everything else.